Figure 2.
Reduction in rheumatoid factor levels in patients who were treated with CZP + MTX in Year 1 and entered the post‐treatment period (CZP + MTX→MTX; N = 108). BL, baseline; CZP, certolizumab pegol; IQR, inter‐quartile range; MTX, methotrexate
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.